CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Immuneering Presents Atebimetinib Phase 3 Pancreatic Cancer Trial Plans, Targets Mid-2028 Topline Data

By Public Technologies
  • Immuneering is enrolling a Phase 3 trial of atebimetinib with modified chemotherapy in first-line pancreatic cancer; topline results are expected mid-2028.
  • Phase 2 data presented at ASCO showed median overall survival of 17.3 months; an update is expected in the first half of 2027.
  • An Astellas collaboration targets CLDN18.2-positive pancreatic cancer with atebimetinib combinations, including chemotherapy-free regimens.
  • The pipeline also includes Phase 2 lung cancer combinations with Regeneron and Eli Lilly.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk